Cargando…

β-Cell Mass and Type 1 Diabetes: Going, Going, Gone?

OBJECTIVE— β-Cell regeneration is a fundamental but elusive goal for type 1 diabetes research. Our objective is to review newer human and animal studies of β-cell destruction and regeneration and consider the implications for treatment of type 1 diabetes. RESEARCH DESIGN AND METHODS— Recent human an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akirav, Eitan, Kushner, Jake A., Herold, Kevan C.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2008
Materias:	Perspectives in Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570380/ https://www.ncbi.nlm.nih.gov/pubmed/18971435 http://dx.doi.org/10.2337/db07-1817

Ejemplares similares

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

How Does Type 1 Diabetes Develop?: The Notion of Homicide or β-Cell Suicide Revisited
por: Atkinson, Mark A., et al.
Publicado: (2011)

Going, Going, Gone: Is Animal Migration Disappearing
por: Wilcove, David S, et al.
Publicado: (2008)

The Kraepelinian dichotomy – going, going... but still not gone
por: Craddock, Nick, et al.
Publicado: (2010)

Rheumatoid vasculitis: going, going, but not yet gone
por: Pisetsky, David S
Publicado: (2015)

Going, going, gone: competitive decision-making in Dutch auctions
por: Bennett, Murray, et al.
Publicado: (2020)

Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?
por: O’Kell, Allison L., et al.
Publicado: (2017)

Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice: Control of Islet Vasculature and Vascular Endothelial Growth Factor by Glucose
por: Akirav, Eitan M., et al.
Publicado: (2011)

Going, Going, Gone: Characterizing the Time-Course of Congruency Sequence Effects
por: Egner, Tobias, et al.
Publicado: (2010)

Immune Therapy and β-Cell Death in Type 1 Diabetes
por: Lebastchi, Jasmin, et al.
Publicado: (2013)

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes
por: Eizirik, Decio L., et al.
Publicado: (2021)

Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
por: Greenbaum, Carla J., et al.
Publicado: (2012)

To Boldly Go Where No Data Stream Has Gone Before
por: Pearson, Ezzy
Publicado: (2020)

Inflammation: Gone with Translation
por: Vinuesa, Carola G., et al.
Publicado: (2014)

Quorum sensing going wild
por: Spacapan, Mihael, et al.
Publicado: (2023)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

β-Cell Failure in Type 2 Diabetes: A Case of Asking Too Much of Too Few?
por: Costes, Safia, et al.
Publicado: (2013)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

Protein Kinase C Function in Muscle, Liver, and β-Cells and Its Therapeutic Implications for Type 2 Diabetes
por: Schmitz-Peiffer, Carsten, et al.
Publicado: (2008)

Hypoglycemia in Type 1 Diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2010)

The Streetlight Effect in Type 1 Diabetes
por: Battaglia, Manuela, et al.
Publicado: (2015)

It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes
por: Creusot, Rémi J., et al.
Publicado: (2014)

From the bench to the bedside: BOLDly going where no one has gone before
por: Hauptman, Jason S.
Publicado: (2010)

Where have all the GPs gone – where will they go? Study of Finnish GPs
por: Sumanen, Markku, et al.
Publicado: (2012)

Genetics of Type 1 Diabetes: What's Next?
por: Pociot, Flemming, et al.
Publicado: (2010)

Immunomodulation by Mesenchymal Stem Cells : A Potential Therapeutic Strategy for Type 1 Diabetes
por: Abdi, Reza, et al.
Publicado: (2008)

Viral Trigger for Type 1 Diabetes: Pros and Cons
por: Filippi, Christophe M., et al.
Publicado: (2008)

Central Role for Interleukin-2 in Type 1 Diabetes
por: Hulme, Maigan A., et al.
Publicado: (2012)

Antigen-Based Therapy for the Treatment of Type 1 Diabetes
por: Tian, Jide, et al.
Publicado: (2009)

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021)

MicroRNAs in β-Cell Biology, Insulin Resistance, Diabetes and Its Complications
por: Fernandez-Valverde, Selene L., et al.
Publicado: (2011)

Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes
por: Sellmeyer, Deborah E., et al.
Publicado: (2016)

Going, Going, Gone The Diminishing Capacity of Museum Specimen Collections to Address Global Change Research: A Case Study on Urban Reptiles
por: Li, Yanlin, et al.
Publicado: (2023)

Whatever can go wrong, need not go wrong: Open Quality approach for epidemiology
por: Alba, Sandra, et al.
Publicado: (2021)

The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes
por: Wahren, John, et al.
Publicado: (2012)

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
por: Peakman, Mark, et al.
Publicado: (2010)

The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes
por: Purcell, Anthony W., et al.
Publicado: (2019)

Diabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention
por: Charles, M. Arthur, et al.
Publicado: (2021)

Where Have All the Crop Phenotypes Gone?
por: Zamir, Dani
Publicado: (2013)

Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure?
por: Dunne, Jessica L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nor8gjl6h2h75l3b13iddn6p35